State Street
TELO icon

State Street’s Telomir Pharmaceuticals TELO Stock Holding History

State Street’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.2K Hold
58,600
– – ﹤0.01% 4074
2025
Q4 		$77.9K Hold
58,600
– – ﹤0.01% 4088
2025
Q3 		$81.5K Sell
58,600
-3,000
-5% -$4.52K ﹤0.01% 4084
2025
Q2 		$77K Sell
61,600
-64,073
-51% -$148K ﹤0.01% 4019
2025
Q1 		$406K Buy
125,673
+9,879
+9% +$43.2K ﹤0.01% 3636
2024
Q4 		$477K Buy
115,794
+79,700
+221% +$376K ﹤0.01% 3628
2024
Q3 		$232K Buy
36,094
+17,967
+99% +$87.6K ﹤0.01% 3791
2024
Q2 		$87.2K Buy
+18,127
New +$113K ﹤0.01% 4045

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

State Street's TELO Position: Q1 2026 in Review

State Street held its Telomir Pharmaceuticals (TELO) position steady in Q1 2026 at 58,600 shares worth $76.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4074.

State Street first reported a position in TELO in Q2 2024 and has held it in 8 quarters since. The position peaked at $477K in Q4 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • State Street held 58,600 shares of Telomir Pharmaceuticals worth $76.2K as of Q1 2026.
  • State Street left its Telomir Pharmaceuticals share count unchanged in Q1 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4074 holding.
  • State Street first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • State Street's Telomir Pharmaceuticals position peaked at $477K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.